Nephros Return on Equity (ROE) Growth & History (NEPH)
Nephros's return on equity was 12.71% for fiscal 2025.
View full Nephros company overviewNephros annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 12.71% | +11.84 pp |
| 2024 | 2024-12-31 | 0.87% | +23.45 pp |
| 2023 | 2023-12-31 | −22.58% | +59.63 pp |
| 2022 | 2022-12-31 | −82.21% | −50.28 pp |
| 2021 | 2021-12-31 | −31.94% | +20.70 pp |
| 2020 | 2020-12-31 | −52.64% | +22.40 pp |
| 2019 | 2019-12-31 | −75.04% | +43.33 pp |
| 2018 | 2018-12-31 | −118.37% | −56.55 pp |
| 2017 | 2017-12-31 | −61.83% | — |
| 2012 | 2012-12-31 | −1,603.63% | −704.15 pp |
| 2011 | 2011-12-31 | −899.49% | −1270.25 pp |
| 2010 | 2010-12-31 | 370.76% | — |
Nephros quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 10.56% | +8.05 pp |
| Q1 2026 | 2026-03-31 | 1.34% | −4.90 pp |
| Q4 2025 | 2025-12-31 | 0.61% | −3.55 pp |
| Q3 2025 | 2025-09-30 | 3.44% | +1.16 pp |
| Q2 2025 | 2025-06-30 | 2.51% | +6.10 pp |
| Q1 2025 | 2025-03-31 | 6.24% | +8.29 pp |
| Q4 2024 | 2024-12-31 | 4.16% | +11.87 pp |
| Q3 2024 | 2024-09-30 | 2.27% | +4.38 pp |
| Q2 2024 | 2024-06-30 | −3.59% | +1.35 pp |
| Q1 2024 | 2024-03-31 | −2.04% | +2.18 pp |
| Q4 2023 | 2023-12-31 | −7.70% | +5.26 pp |
| Q3 2023 | 2023-09-30 | −2.11% | +39.52 pp |
| Q2 2023 | 2023-06-30 | −4.93% | +6.80 pp |
| Q1 2023 | 2023-03-31 | −4.22% | +13.78 pp |
| Q4 2022 | 2022-12-31 | −12.96% | −4.77 pp |
| Q3 2022 | 2022-09-30 | −41.63% | −31.53 pp |
| Q2 2022 | 2022-06-30 | −11.73% | −2.51 pp |
| Q1 2022 | 2022-03-31 | −18.00% | −13.71 pp |
| Q4 2021 | 2021-12-31 | −8.19% | −0.93 pp |
| Q3 2021 | 2021-09-30 | −10.09% | +1.39 pp |
| Q2 2021 | 2021-06-30 | −9.22% | +7.49 pp |
| Q1 2021 | 2021-03-31 | −4.29% | +10.09 pp |
| Q4 2020 | 2020-12-31 | −7.26% | −3.83 pp |
| Q3 2020 | 2020-09-30 | −11.49% | +8.31 pp |
| Q2 2020 | 2020-06-30 | −16.72% | +12.69 pp |
| Q1 2020 | 2020-03-31 | −14.38% | +27.76 pp |
| Q4 2019 | 2019-12-31 | −3.43% | +15.00 pp |
| Q3 2019 | 2019-09-30 | −19.80% | −6.58 pp |
| Q2 2019 | 2019-06-30 | −29.41% | −8.08 pp |
| Q1 2019 | 2019-03-31 | −42.14% | +32.13 pp |
| Q4 2018 | 2018-12-31 | −18.44% | −134.82 pp |
| Q3 2018 | 2018-09-30 | −13.22% | +107.39 pp |
| Q2 2018 | 2018-06-30 | −21.33% | +51.55 pp |
| Q1 2018 | 2018-03-31 | −74.27% | −7.64 pp |
| Q4 2017 | 2017-12-31 | 116.39% | +185.92 pp |
| Q3 2017 | 2017-09-30 | −120.61% | −71.75 pp |
| Q2 2017 | 2017-06-30 | −72.88% | −27.33 pp |
| Q1 2017 | 2017-03-31 | −66.63% | — |
| Q4 2016 | 2016-12-31 | −69.53% | +1391.40 pp |
| Q3 2016 | 2016-09-30 | −48.86% | — |
| Q2 2016 | 2016-06-30 | −45.55% | — |
| Q4 2015 | 2015-12-31 | −1,460.94% | — |
| Q2 2014 | 2014-06-30 | −1,087.37% | — |
| Q3 2013 | 2013-09-30 | −378.91% | −239.08 pp |
| Q3 2012 | 2012-09-30 | −139.84% | −119.60 pp |
| Q2 2012 | 2012-06-30 | −78.09% | −27.14 pp |
| Q1 2012 | 2012-03-31 | −45.38% | — |
| Q4 2011 | 2011-12-31 | −322.30% | — |
| Q3 2011 | 2011-09-30 | −20.24% | — |
| Q2 2011 | 2011-06-30 | −50.95% | — |
Nephros return on equity trends
Over the last five fiscal years, Nephros's return on equity increased from −52.64% to 12.71%, a change of +65.35 percentage points. The latest reported quarter, Q2 2026, shows 10.56%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nephros source filings ↗